Evaluation of apoptotic marker Bcl2, CD4+, human hepatocyte growth factor and metalloproteinase-9 as tumor markers for patients with hepatocellular carcinoma

被引：2

作者：

Youness E.R. ^{[1
]}

El Nemr M. ^{[2
]}

Oraby F.S. ^{[1
]}

Ahmed N.M. ^{[1
]}

Moghni M.A. ^{[3
]}

Aly H.F. ^{[4
]}

Ahmed H.H. ^{[5
]}

机构：

[1] Medical Biochemistry Department, National Research Center, Dokki, Giza

[2] Internal Medicine Department, 6 October University, Cairo

[3] Internal Medicine Department, Ain Shams University, Cairo

[4] Therapeutic Chemistry Department, National Research Center, Dokki, Giza

[5] Hormones Department, National Research Center, Dokki, Giza

来源：

Indian Journal of Clinical Biochemistry | 2014年 / 29卷 / 3期

关键词：

HCC; HGF; MMP-9;

D O I：

10.1007/s12291-013-0381-5

中图分类号：

学科分类号：

摘要：

To examine the possible involvement of human B cell leukemia/lymphoma 2 (Bcl-2), CD4+ cells, hepatocyte growth factor (HGF), and metalloproteinase-9 (MMP-9), as biomarkers in early diagnosis of hepatocellular carcinoma (HCC), activities of these biomarkers in serum were demonstrated by the method of Enzyme Linked Immunosorbant Assay. Two groups of subjects (60 for each), were examined in this study; healthy controls and patients with HCC. The present results declare that, significant decrease in Bcl-2 (p ≤ 0.0001), and CD 4+ (p ≤ 0.001), while significant increase in HGF and MMP-9 (p ≤ 0.05). These findings imply an influence of these biomarkers by the existence of hepatic carcinoma that might reflect the progression of disease and a distinction between the pathological mechanisms involved in hepatic carcinoma. Since, the serum MMP-9 activity was significantly varied between each stage of HCC. An individual profile of the present investigated parameters was detected that might serve as an easy accessing serum marker to monitor the progression of hepatic cell disorders. © 2013 Association of Clinical Biochemists of India.

引用

页码：351 / 356

页数：5

共 37 条

[1]

Bosch F.X., Ribes J., Diaz M., Cleries R., Primary liver cancer: Worldwide incidence and trends, Gastroenterology, 127, (2004)

[2]

Llovet J.M., Bruix J., Molecular targeted therapies in hepatocellular carcinoma, Hepatology, 48, pp. 1312-1327, (2008)

[3]

Lee J.-S., Thorgeirsson S.S., Comparative and integrative functional genomics of HCC, Oncogene, 25, 27, pp. 3801-3809, (2006)

[4]

Frau M., Biasi F., Feo F., Pascale R.M., Prognostic markers and putative therapeutic targets for hepatocellular carcinoma, Mol Aspects Med, 31, pp. 179-193, (2010)

[5]

Bruix J., Sherman M., Management of hepatocellular carcinoma: An update, Hepatology, 53, pp. 1020-1022, (2011)

[6]

Shih T.-C., Tien Y.-J., Wen C.-J., Yeh T.-S., Ming-Chin Y., Huang C.-H., Lee Y.-S., Yen T.-C., Hsieh S.-Y., MicroRNA-214 down regulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma, J Hepatol, 57, pp. 584-591, (2012)

[7]

Hsia C.Y., Huo T.I., Chiang S.Y., Lu M.F., Sun C.L., Wu J.C., Lee P.C., Chi C.W., Lui W.Y., Lee S.D., Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma, EJSO, 33, pp. 208-212, (2007)

[8]

Mazzanti R., Platini F., Bottini C., Fantappie O., Solazzo M., Tessitore L., Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line, Biochem Pharmacol, 78, pp. 21-32, (2009)

[9]

Rubinsztein D.C., Gestwicki J.E., Murphy L.O., Klionsky D.J., Potential therapeutic applications of autophagy, Nature Reviews Drug Discovery, 6, 4, pp. 304-312, (2007)

[10]

Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., Rosen J., Eskelinen E.-L., Mizushima N., Ohsumi Y., Cattoretti G., Levine B., Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene, Journal of Clinical Investigation, 112, 12, pp. 1809-1820, (2003)

← 1 2 3 4 →